Author

Daria A. Barsova

Observed names: D. A. Barsova, D. Barsova, D. А. Barsova, Daria Barsova

Institution: State Budget Institution of Health St. Petersburg Clinical Research Center Specialized Types of Medical Care

Observed institution: State Budget Institution of Health St. Petersburg Clinical Research Center Specialized Types of Medical Care

ORCID: 0009-0003-1656-0395

Observed ORCID: 0009-0003-1656-0395

OpenAlex ID: A5080865607

Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients

2023 · Anna P. Sokolenko, Fedor V. Moiseyenko, et al. · International Journal of Molecular Sciences · 2

Analysis of the efficacy and safety of regorafenib versus chemotherapy retreatment in 3rd line treatment of metastatic colorectal cancer

2026 · Grigoriy M. Naydin, D. А. Barsova, et al. · Surgery and Oncology · 1

Choice of the 3rd and the 4th line therapy sequence in patients with metastatic colorectal cancer

2026 · G. M. Naydin, G. G. Makeev, et al. · Malignant tumours

256eP Chemotherapy retreatment versus regorafenib in third-line metastatic colorectal cancer: Survival outcomes, prognostic model, and toxicity profile

2025 · G. Naydin, G.G. Makiev, et al. · Annals of Oncology

Baseline Radiomics as a Prognostic Tool for Clinical Benefit from Immune Checkpoint Inhibition in Inoperable NSCLC Without Activating Mutations

2025 · Fedor Moiseenko, Marko Radulovic, et al. · Cancers

Works count: 5

Citation count: 3

H-index: 1

I10-index: